Fig. 1.
Experimental designs used in the current study. Workflow and treatment groups used to determine the effect of genetic deletion of PDE3A on inflammation-induced CMH development (a), pharmacological inhibition of PDE3A with cilostazol on CAA-associated spontaneous CMH development (b), and pharmacological inhibition of PDE3A with cilostazol on inflammation-induced CMH development (c)